A Phase-2 Study of Nivolumab and Ipilimumab Combination, Ipilimumab alone or Cabazitaxel in Men with metastatic, castration-resistant Prostate Cancer (Check Mate-650) - AP 110/20 of AUO Second/Third-Line Therapy after Failure of Docetaxel in Patients with metastatic Prostate Cancer (mCRPC )

被引：0
|
作者：
Rexer, Heidrun [1 ]
Grimm, Marc-Oliver [2 ]
Boegemann, Martin [3 ]
机构：
[1] AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Univ Klinikum Jena, Klin & Poliklin Urol, Leiter Klin Prufung, Klinikum 1, D-07747 Jena, Germany
[3] Deutsch Krebsgesell eV, Organgrp Sprecher Arbeitsgemeinschaft Urol, Kuno Fischer Str 8, D-14057 Berlin, Germany
来源：
AKTUELLE UROLOGIE | 2021年 / 52卷 / 04期
关键词：
D O I：
10.1055/a-1469-0239
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：316 / 317
页数：2
相关论文
共 50 条
  • [1] Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer
    Kongsted, Per
    Svane, Inge M.
    Lindberg, Henriette
    Bisbjerg, Rasmus
    Daugaard, Gedske
    Sengelov, Lisa
    ANTI-CANCER DRUGS, 2016, 27 (07) : 695 - 701
  • [2] First and Second-line Therapy for metastatic castration-refractory Prostate Cancer (mCRPC) A Phase II Study of Nivolumab in combination with Rucaparib, Docetaxel or Enzalutamide in Men with castration-resistant metastatic Prostate Cancer (CheckMate-9KD) - AP 103/18 of AUO
    Rexer, H.
    Hammerer, P.
    Gruellich, C.
    UROLOGE, 2019, 58 (04): : 475 - 476
  • [3] Phase III Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC): A randomized, double-blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with metastatic castration-resistant Prostate Cancer (CheckMate-7DX) - AUO Study AP 118/21
    Rexer, Heidrun
    Boegemann, Martin
    Hammerer, Peter
    AKTUELLE UROLOGIE, 2022, 53 (03) : 226 - 228
  • [4] Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Slovin, S. F.
    Beer, T. M.
    Higano, C. S.
    Tejwani, S.
    Hamid, O.
    Picus, J.
    Harzstark, A.
    Scher, H. I.
    Lan, Z.
    Lowy, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase-III Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) A randomized, double-blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with metastatic castration-resistant Prostate Cancer (CheckMate-7DX) - Study AP 118/21 of the AUO
    Rexer, H.
    Boegemann, M.
    Hammerer, P.
    UROLOGE, 2022, 61 (03): : 345 - 346
  • [6] Initial Results From a Phase 2 Study of Nivolumab Plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 8 - 10
  • [7] Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Beer, T. M.
    Slovin, S. F.
    Higano, C. S.
    Tejwani, S.
    Dorff, T. B.
    Stankevich, E.
    Lowy, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
    Sharma, Padmanee
    Pachynski, Russell Kent
    Narayan, Vivek
    Flechon, Aude
    Gravis, Gwenaelle
    Galsky, Matt D.
    Mahammedi, Hakim
    Patnaik, Akash
    Subudhi, Sumit Kumar
    Ciprotti, Marika
    Duan, Tao
    Saci, Abdel
    Hu, Sarah
    Han, G. Celine
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [10] Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
    Massard, C.
    Mateo, J.
    Loriot, Y.
    Pezaro, C.
    Albiges, L.
    Mehra, N.
    Varga, A.
    Bianchini, D.
    Ryan, C. J.
    Petrylak, D. P.
    Attard, G.
    Shen, L.
    Fizazi, K.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2017, 28 (01) : 90 - 95
12345